IP Library Granted Patent US 12,291,720
Granted Patent B2
US 12,291,720 · App. 17/567,708 · Granted May 6, 2025

Production method for retinal tissue

Inventors: Atsushi Kuwahara (Kobe, JP); Suguru Yamasaki (Kobe, JP); Yasushi Hiramine (Kobe, JP); Yoshiki Sasai (Wako, JP); Masayo Takahashi (Wako, JP)
Assignees: SUMITOMO PHARMA CO., LTD.; RIKEN
C12N5/0621A61K35/30A61K35/44A61L27/00A61L27/383A61L27/3895C12N5/0619C12N5/0623C12Q1/02G01N33/5014G01N33/5058C12N2501/115C12N2501/155C12N2501/41C12N2501/50C12N2501/999C12N2506/45C12N2533/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,291,720
App. No.
17/567,708
Granted
May 6, 2025
Kind
B2
Abstract

The present invention provides a method for producing retinal cells or a retinal tissue, comprising the following steps (1)-(3): (1) a first step of culturing human pluripotent stem cells in the absence of feeder cells and in a medium comprising a factor for maintaining undifferentiated state, (2) a second step of culturing the pluripotent stem cells obtained in the first step in suspension in the presence of a Sonic hedgehog signal transduction pathway activating substance to form a cell aggregate, and (3) a third step of culturing the aggregate obtained in the second step in suspension in the presence of a 1) a BMP signal transduction pathway activating substance to obtain an aggregate containing retinal cells or a retinal tissue.

Claims (20)

1. A method for producing a cell aggregate containing a mixture of cells expressing Oct3/4 and cells expressing at least one kind selected from the group consisting of SOX1, N-cadherin, OTX2 and Nestin, comprising the following steps (1) and (2):

(1) a first step of culturing human pluripotent stem cells in the absence of feeder cells and in a medium comprising a factor for maintaining undifferentiated state of the human pluripotent stem cells, and

(2) a second step of dispersing the cells obtained in the first step and culturing the dispersed cells in suspension in the presence of a Sonic hedgehog signal transduction pathway activating substance in the absence of a Wnt signal transduction pathway inhibiting substance to form a cell aggregate within about 72 hours after the cells obtained in the first step are dispersed.

2. The production method according to claim 1 , wherein the factor for maintaining undifferentiated state is an FGF signal transduction pathway activating substance.

3. The production method according to claim 2 , wherein the FGF signal transduction pathway activating substance is bFGF.

4. The production method according to claim 1 , wherein, in the second step, the concentration of the Sonic hedgehog signal transduction pathway activating substance in the medium is a concentration corresponding to Sonic hedgehog signal transduction activity of SAG at 10 nM to 700 nM.

5. The production method according to claim 1 , wherein the Sonic hedgehog signal transduction pathway activating substance is SAG, Purmorphamine or Shh.

6. The production method according to claim 1 , wherein the first step is performed by an adhesion culturing method.

7. The production method according to claim 1 , wherein the pluripotent stem cells are induced pluripotent stem cells.

8. The production method according to claim 1 , wherein uniform aggregates are formed.

9. The production method according to claim 1 , wherein the cell aggregate maintaining an undifferentiated state is formed.

10. The production method according to claim 1 , wherein the percentage of cells expressing Oct3/4 is not less than 50% of the total number of cells in the cell aggregates.

11. The production method according to claim 1 , wherein, in the second step, the suspension culturing is performed in a serum-free medium.

12. The production method according to claim 1 , wherein a period for the culturing in the second step is 12 hr-48 hr.

13. A method for producing a neural cell or neural tissue comprising a step of culturing the cell aggregate obtained in claim 1 in suspension.

14. The method according to claim 13 , wherein the culturing in suspension is performed in the absence of BMP signal transduction pathway activating substance.

15. The method according to claim 13 , wherein the neural cell and neural tissue comprise a cell expressing Sox2 and/or Pax6.

16. The method according to claim 13 , wherein the culturing in suspension is performed using a medium free of a Sonic hedgehog signal transduction pathway activating substance, or wherein the culturing in suspension is performed using a medium comprising a Sonic hedgehog signal transduction pathway activating substance and stepwisely decreasing the concentration of the Sonic hedgehog signal transduction pathway activating substance in the medium.

17. The method according to claim 16 , wherein the decreasing of the concentration of the Sonic hedgehog signal transduction pathway activating substance is performed by changing a half amount of the existing medium to a serum-containing medium or serum-free medium free of the Sonic hedgehog signal transduction pathway activating substance.

18. The method according to claim 17 , wherein the medium change is performed 1 to 4 times.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 30, 2025
From: SUMITOMO PHARMA CO., LTD.
To: RACTHERA CO., LTD.
Reel/Frame 072825/0888 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 4, 2024
From: SUMITOMO CHEMICAL COMPANY, LIMITED
To: SUMITOMO PHARMA CO., LTD.
Reel/Frame 068799/0134 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2024
From: KUWAHARA, ATSUSHI; YAMASAKI, SUGURU; HIRAMINE, YASUSHI; SASAI (LEGAL REPRESENTATIVE OF THE DECEASED INVENTOR YOSHIKI SASAI), MIYUKI; TAKAHASHI, MASAYO
To: SUMITOMO DAINIPPON PHARMA CO., LTD.; RIKEN; SUMITOMO CHEMICAL COMPANY, LIMITED
Reel/Frame 067185/0569 →
NAME AND ADDRESS CHANGE Recorded May 4, 2022
From: SUMITOMO DAINIPPON PHARMA CO., LTD.
To: SUMITOMO PHARMA CO., LTD.
Reel/Frame 059855/0333 →
Priority Claims (1)
JP 2014-217868 · Oct 24, 2014 · national
Continuity (2)
Continuation 15521387
Related Publication 20220119764A1 · Apr 21, 2022
References Cited (111)
US 8956866B2 · Idelson et al. · 2015 [cited by applicant]
US 11214772B2 · Kuwahara et al. · 2022 [cited by applicant]
US 20060122111A1 · Furukawa · 2006 [cited by applicant]
US 20080044901A1 · Sasai et al. · 2008 [cited by applicant]
US 20090053809A1 · Zander et al. · 2009 [cited by applicant]
US 20100009442A1 · Sasai et al. · 2010 [cited by applicant]
US 20100119492A1 · Hans et al. · 2010 [cited by applicant]
US 20110027333A1 · Idelson et al. · 2011 [cited by applicant]
US 20110091869A1 · Sasai et al. · 2011 [cited by applicant]
US 20110223140A1 · Park et al. · 2011 [cited by applicant]
US 20110274662A1 · Malcuit et al. · 2011 [cited by applicant]
US 20120129211A1 · Kattman et al. · 2012 [cited by applicant]
US 20130040330A1 · Sasai et al. · 2013 [cited by applicant]
US 20140308743A1 · Sasai et al. · 2014 [cited by applicant]
US 20140341864A1 · Nakano et al. · 2014 [cited by applicant]
US 20150118749A1 · Idelson et al. · 2015 [cited by applicant]
US 20150125506A1 · Idelson et al. · 2015 [cited by applicant]
US 20150132787A1 · Sasai et al. · 2015 [cited by applicant]
US 20160186134A1 · Keller et al. · 2016 [cited by applicant]
US 20160186136A1 · Sasai et al. · 2016 [cited by applicant]
US 20160244721A1 · Sawada et al. · 2016 [cited by applicant]
US 20160251616A1 · Nakano et al. · 2016 [cited by applicant]
US 20160264936A1 · Nakano et al. · 2016 [cited by applicant]
US 20160376554A1 · Kuwahara et al. · 2016 [cited by applicant]
US 20170253853A1 · Sasai et al. · 2017 [cited by applicant]
US 20170313976A1 · Kuwahara et al. · 2017 [cited by applicant]
US 20170313981A1 · Kuwahara et al. · 2017 [cited by applicant]
US 20170319748A1 · Kuwahara et al. · 2017 [cited by applicant]
US 20180245039A1 · Ando et al. · 2018 [cited by applicant]
US 20180258388A1 · Ando et al. · 2018 [cited by applicant]
US 20190127670A1 · Kuwahara et al. · 2019 [cited by applicant]
CN 101688178A · 2010 [cited by applicant]
EP 2128244A1 · 2009 [cited by applicant]
JP 2012507285A · 2012 [cited by applicant]
JP 2012070731A · 2012 [cited by applicant]
JP 2012245007A · 2012 [cited by applicant]
JP 2013099345A · 2013 [cited by applicant]
WO WO2006053629A1 · 2006 [cited by applicant]
WO WO2009148170A1 · 2009 [cited by applicant]
WO WO2011043591A2 · 2011 [cited by applicant]
WO WO2011055855A1 · 2011 [cited by applicant]
WO WO2012135621A2 · 2012 [cited by applicant]
WO WO2013065763A1 · 2013 [cited by applicant]
WO WO2013077425A1 · 2013 [cited by applicant]
WO WO2015025967A1 · 2015 [cited by applicant]
WO WO2015053375A1 · 2015 [cited by applicant]
WO WO2015054526A2 · 2015 [cited by applicant]
WO WO2015068505A1 · 2015 [cited by applicant]
WO WO2015107738A1 · 2015 [cited by applicant]
WO WO2016032263A1 · 2016 [cited by applicant]
WO WO2016039317A1 · 2016 [cited by applicant]
WO WO2016063985A1 · 2016 [cited by applicant]
WO WO2016063986A1 · 2016 [cited by applicant]
WO WO2017043604A1 · 2017 [cited by applicant]
WO WO2017043605A1 · 2017 [cited by applicant]
Akopian et al., “Comparison of defined culture systems for feeder cell free propagation of human embryonic stem cells,” In Vitro [cited by applicant]
Amoroso et al., “Accelerated High-Yield Generation of Limb-Innervating Motor Neurons from Human Stem Cells,” [cited by applicant]
Boucherie et al., “Brief Report: Self-Organizing Neuroepithelium from Human Pluripotent Stem Cells Facilitates Derivation of Photoreceptors,” [cited by applicant]
Chambers et al., “Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling,” [cited by applicant]
Chen, “Chemically defined conditions for human iPSC derivation and culture,” [cited by applicant]
Davis-Dusenbery et al., “How to make spinal motor neurons,” [cited by applicant]
Denayer et al., “Canonical Wnt Signaling Controls Proliferation of Retinal Stem/Progenitor Cells in Postembryonic Xenopus Eyes,” [cited by applicant]
Doi et al., “Isolation of Human Induced Pluripotent Stem Cell-Derived Dopaminergic Progenitors by Cell Sorting for Successful Transplantation,” [cited by applicant]
Du et al., “Regulation of Retinal Progenitor Cell Differentiation by Bone Morphogenetic Protein 4 is Mediated by the Smad/Id Cascade,” [cited by applicant]
Eiraku, “Self-Organized Formation of Polarized Cortical Tissues from ESCs and Its Active Manipulation by Extrinsic Signals,” [cited by applicant]
Eiraku et al., “Relaxation-expansion model for self-driven retinal morphogenesis,” [cited by applicant]
Eiraku et al., “Self-organizing optic-cup morphogenesis in three-dimensional culture,” [cited by applicant]
Faravelli et al., “Motor neuron derivation from human embryonic and induced pluripotent stem cells: experimental approaches and clinical perspectives,” [cited by applicant]
Fuhrmann, “Wnt signaling in eye organogenesis,” [cited by applicant]
Furuta et al., “BMP4 is essential for lens induction in the mouse embryo,” [cited by applicant]
Hu et al., “Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency,” [cited by applicant]
Ikeda et al., “In vitro neuronal differentiation induction using ES cells—telencephalic precursors and neural retinal precursors,” [cited by applicant]
Kadoshima et al., “Self-organization of axial polarity, inside-out layer pattern, and species-specific progenitor dynamics in human ES cell-derived neocortex,” [cited by applicant]
Kubo et al., “Wnt2b controls retinal cell differentiation at the ciliary marginal zone,” [cited by applicant]
Kubo et al., “Hairy1 acts as a node downstream of Wnt signaling to maintain retinal stem cell-like progenitor cells in the chick ciliary marginal zone,” [cited by applicant]
Kuwahara et al., “Generation of a ciliary margin-like stem cell niche from self- organizing human retinal tissue,” [cited by applicant]
Lamba et al., “Efficient generation of retinal progenitor cells from human embryonic stem cells,” [cited by applicant]
Lancaster et al., “Cerebral organoids model human brain development and microcephaly,” [cited by applicant]
Lang, “Pathways regulating lens induction in the mouse,” [cited by applicant]
La Torre et al., “Production and Transplantation of Retinal Cells from Human and Mouse Embryonic Stem Cells,” [cited by applicant]
Loebel et al., “Lineage choice and differentiation in mouse embryos and embryonic stem cells,” [cited by applicant]
Messina et al., “Noggin-Mediated Retinal Induction Reveals a Novel Interplay Between Bone Morphogenetic Protein Inhibition, Transforming Growth Factor β, and Sonic Hedgehog Signaling,” [cited by applicant]
Miyazawa et al., “Two major Smad pathways in TGF-beta superfamily signaling,” [cited by applicant]
Morizane et al., “Neural Induction with a Dopaminergic Phenotype from Human Pluripotent Stem Cells Through a Feeder-Free Floating Aggregation Culture,” [cited by applicant]
Muguruma et al., “Ontogeny-recapitulating generation and tissue integration of ES cell-derived Purkinje cells,” [cited by applicant]
Nakagawa et al., “A novel efficient feeder-free culture system for the derivation of human induced pluripotent stem cells,” [cited by applicant]
Nakano et al., “Self-Formation of Optic Cups and Storable Stratified Neural Retina from Human ESCs,” [cited by applicant]
Osakada et al., “Control of neural differentiation from pluripotent stem cells,” [cited by applicant]
Osakada et al., “Toward the generation of rod and con photoreceptors from mouse, monkey and human embryonic stem cells,” [cited by applicant]
Osakada et al., “In vitro differentiation of retinal cells from human pluripotent stem cells by small-molecule induction,” [cited by applicant]
Osakada et al., “Neural Induction and Patterning in Mammalian Pluripotent Stem Cells,” [cited by applicant]
Ozair, “Neural induction and early patterning in vertebrates,” [cited by applicant]
Sasai, “Self-organization as seen in pattern formation of neural tissue: Challenge to Emergent Biology,” [cited by applicant]
Seiler et al., “Visual restoration and transplant connectivity in degenerate rats implanted with retinal progenitor sheets,” [cited by applicant]
Stanton et al., “Small-molecule modulators of the [cited by applicant]
Stephens et al., “Loss of [cited by applicant]
Suga et al., “Self-formation of functional adenohypophysis in three-dimensional culture,” [cited by applicant]
Trousse et al., “BMP4 Mediates Apoptotic Cell Death in the Developing Chick Eye,” [cited by applicant]
Vugler et al., “Embryonic stem cells and retinal repair,” [cited by applicant]
Watanabe et al., “Directed differentiation of telencephalic precursors from embryonic stem cells,” [cited by applicant]
Wei et al., “Isolation and identification of retinal stem cells in mouse eye,” [cited by applicant]
Yang et al., “Directed Differentiation into Neural Lineages and Therapeutic Potential of Porcine Embryonic Stem Cells in Rat Parkinson's Disease Model,” [cited by applicant]
Yang et al., “Efficient generation of lens progenitor cells and lentoid bodies from human embryonic stem cells in chemically defined conditions,” [cited by applicant]
Zhang et al., “Rapid and Efficient Generation of Neurons from Human Pluripotent Stem Cells in a Multititre Plate Format,” [cited by applicant]
Zhou et al., “Differentiation of human embryonic stem cells into cone photoreceptors through simultaneous inhibition of BMP, TGFβ and Wnt signaling,” [cited by applicant]
European Patent Office, Supplementary European Search Report in European Patent Application No. 15852025 (Apr. 20, 2018). [cited by applicant]
European Patent Office, Communication Pursuant to Rule 164(1) EPC in European Patent Application No. 15852504.8 (May 14, 2018). [cited by applicant]
European Patent Office, Extended European Search Report in European Patent Application No. 15852504.8 (Sep. 6, 2018). [cited by applicant]
European Patent Office, Extended European Search Report in European Patent Application No. 17786064.0 (Oct. 17, 2019). [cited by applicant]
European Patent Office, Extended European Search Report in European Patent Application No. 21166628.4 (Jul. 19, 2021). [cited by applicant]
Japanese Patent Office, International Search Report in International Patent Application No. PCT/JP2017/016120 (Jul. 11, 2017). [cited by applicant]
Cited By (1)
US 12,716,826